Document Detail

Detection of impaired homologous recombination repair in NSCLC cells and tissues.
MedLine Citation:
PMID:  23399959     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Homologous recombination repair (HRR) is a critical pathway for the repair of DNA damage caused by cisplatin or poly-ADP ribose polymerase (PARP) inhibitors. HRR may be impaired by multiple mechanisms in cancer, which complicates assessing the functional HRR status in cells. Here, we monitored the ability of non-small-cell lung cancer (NSCLC) cells to form subnuclear foci of DNA repair proteins as a surrogate of HRR proficiency.
METHODS: We assessed clonogenic survival of 16 NSCLC cell lines in response to cisplatin, mitomycin C (MMC), and the PARP inhibitor olaparib. Thirteen tumor explants from patients with NSCLC were subjected to cisplatin ex vivo. Cells were assayed for foci of repair-associated proteins such as BRCA1, FANCD2, RAD51, and γ-H2AX.
RESULTS: Four cell lines (25%) showed an impaired RAD51 foci-forming ability in response to cisplatin. Impaired foci formation correlated with cellular sensitivity to cisplatin, MMC and olaparib. Foci responses complemented or superseded genomic information suggesting alterations in the ATM/ATR and FA/BRCA pathways. Because baseline foci in untreated cells did not predict drug sensitivity, we adapted an ex vivo biomarker assay to monitor damage-induced RAD51 foci in NSCLC explants from patients. Ex vivo cisplatin treatment of explants identified two tumors (15%) exhibiting compromised RAD51 foci induction.
CONCLUSIONS: A fraction of NSCLC harbors HRR defects that may sensitize the affected tumors to DNA-damaging agents including PARP inhibitors. We propose that foci-based functional biomarker assays represent a powerful tool for prospective determination of treatment sensitivity, but will require ex vivo techniques for induction of DNA damage to unmask the underlying HRR defect.
Moritz Birkelbach; Natalie Ferraiolo; Liliana Gheorghiu; Heike N Pfäffle; Benedict Daly; Michael I Ebright; Cheryl Spencer; Carl O'Hara; Johnathan R Whetstine; Cyril H Benes; Lecia V Sequist; Lee Zou; Jochen Dahm-Daphi; Lisa A Kachnic; Henning Willers
Related Documents :
15290849 - Suppression of the progress of disseminated pancreatic cancer cells by nk4 plasmid dna ...
22991469 - A kinetic clutch governs religation by type ib topoisomerases and determines camptothec...
24186019 - Assessment of dna pooling strategies for mapping of qtls.
24280829 - Cre recombinase induces dna damage and tetraploidy in the absence of loxp sites.
24852749 - Genotoxic klebsiella pneumoniae in taiwan.
23948319 - Can brothers share the same str profile?
22394339 - Assessment of the adverse effects of the acaricide amitraz: in vitro evaluation of geno...
3579919 - Reduced thiol content in l1210 cells treated with bso increases dna crosslinking by mel...
1683329 - Genetic stability of the d1z2 region: implications for dna genotyping and paternity tes...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  8     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-14     Completed Date:  2013-07-30     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  279-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / pharmacology
Antineoplastic Agents / pharmacology*
BRCA1 Protein / metabolism
Carcinoma, Non-Small-Cell Lung / diagnosis,  drug therapy,  genetics*
Cisplatin / pharmacology
DNA Damage / drug effects,  genetics
Fanconi Anemia Complementation Group D2 Protein / metabolism
Immunoenzyme Techniques
Lung Neoplasms / diagnosis,  drug therapy,  genetics*
Microscopy, Fluorescence
Mitomycin / pharmacology
Phthalazines / pharmacology
Piperazines / pharmacology
Poly(ADP-ribose) Polymerases / antagonists & inhibitors*
Rad51 Recombinase / metabolism
Recombination, Genetic / genetics*
Recombinational DNA Repair / drug effects,  genetics*
Tumor Cells, Cultured
Tumor Stem Cell Assay
Grant Support
C06 CA059267/CA/NCI NIH HHS; C06 CA059267/CA/NCI NIH HHS; P50 CA090578/CA/NCI NIH HHS; P50 CA090578/CA/NCI NIH HHS; R01 GM097360/GM/NIGMS NIH HHS; R01 GM097360/GM/NIGMS NIH HHS
Reg. No./Substance:
0/AZD 2281; 0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents; 0/BRCA1 Protein; 0/BRCA1 protein, human; 0/FANCD2 protein, human; 0/Fanconi Anemia Complementation Group D2 Protein; 0/Phthalazines; 0/Piperazines; 50SG953SK6/Mitomycin; EC protein, human; EC Polymerases; EC 2.7.7.-/RAD51 protein, human; EC 2.7.7.-/Rad51 Recombinase; Q20Q21Q62J/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?
Next Document:  Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in...